Three - Drug Regimen Treats Cystic Fibrosis in Younger Children
Elexacaftor/tezacaftor/ivacaftor well tolerated in children aged 6 through 11 years with cystic fibrosis and at least one F508del - CFTR allele (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - April 14, 2021 Category: Respiratory Medicine Tags: Family Medicine, Pediatrics, Pharmacy, Pulmonology, Journal, Source Type: news

Three-Drug Regimen Treats Cystic Fibrosis in Younger Children
WEDNESDAY, April 14, 2021 -- The safety and efficacy of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) for the treatment of cystic fibrosis with at least one F508del-CFTR allele in children aged 6 to 11 years are consistent with the results reported... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 14, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic ...
Source: Roche Media News - April 13, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic ...
Source: Roche Investor Update - April 13, 2021 Category: Pharmaceuticals Source Type: news

< a href= " /news-events/nih-research-matters/sweat-sticker-diagnosing-cystic-fibrosis " > “Sweat sticker” for diagnosing cystic fibrosis < /a >
Researchers created a “sweat sticker” for measuring chloride concentrations in sweat, a sign of cystic fibrosis. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - April 13, 2021 Category: Consumer Health News Source Type: news

Bioengineer wins NIH grant to attack cystic fibrosis
(Rice University) Rice University chemical and biomolecular engineer Xue Sherry Gao wins a prestigious National Institutes of Health R01 grant to develop personalized gene editing techniques for cystic fibrosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 8, 2021 Category: International Medicine & Public Health Source Type: news

Cystic Fibrosis: More patients can have wonder drug - hope for hundreds
A WONDER drug that "almost cures" cystic fibrosis can be given to hundreds more English patients. (Source: Daily Express - Health)
Source: Daily Express - Health - April 5, 2021 Category: Consumer Health News Source Type: news

Can a'Sweat Sticker' Improve Diagnosis of Cystic Fibrosis? Can a'Sweat Sticker' Improve Diagnosis of Cystic Fibrosis?
The technology may help clinicians monitor how patients respond to treatment and allow for sweat testing outside of clinical settings, researchers suggest.Medscape Medical News (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - April 2, 2021 Category: Pediatrics Tags: Pediatrics News Source Type: news

A simple sweat test for cystic fibrosis
(Source: ScienceNOW)
Source: ScienceNOW - April 1, 2021 Category: Science Authors: Czajka, C. Tags: twis Source Type: news

Soft " sweat stickers " may streamline diagnosis of cystic fibrosis in children
(American Association for the Advancement of Science) New " sweat stickers " may streamline the early diagnosis of cystic fibrosis by enabling scientists to easily gather and analyze sweat from the skin of infants and children. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 31, 2021 Category: International Medicine & Public Health Source Type: news

Dutch medical AI company Thirona launches software for cystic fibrosis
The new algorithm allows for automated analysis of CT scans of patients with the condition. (Source: mobihealthnews)
Source: mobihealthnews - March 31, 2021 Category: Information Technology Tags: AI, Analytics, Predictive analytics, Data and Information Source Type: news

Liesbeth Stoeffler, 61, Runner Kept Going by Rare Lung Treatment, Dies
A machine that acted as an artificial lung kept her eligible for a transplant as she dealt with cystic fibrosis. She went on to compete again in marathons. (Source: NYT Health)
Source: NYT Health - March 26, 2021 Category: Consumer Health News Authors: Richard Sandomir Tags: Cystic Fibrosis Coronavirus (2019-nCoV) Ventilators (Medical) Lungs Running AllianceBernstein Holding LP Austria Manhattan (NYC) Stoeffler, Liesbeth (1959-2021) Transplants Source Type: news

Thirona launches AI algorithm for cystic fibrosis
Software developer Thirona is launching Pragma-AI, a new artificial intelligenc...Read more on AuntMinnie.comRelated Reading: Thirona licenses patent for cystic fibrosis AI software Meet the Minnies 2020 semifinal candidates Thirona, Smart Reporting team up on COVID-19 software Thirona unveils AI software for COVID-19 analysis AI-based CAD accurately detects tuberculosis on chest x-rays (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 25, 2021 Category: Radiology Source Type: news

Therapy for most common cause of cystic fibrosis safe and effective in 6-11
(Ann& Robert H. Lurie Children's Hospital of Chicago) An international, open-label Phase 3 study, co-led by Susanna McColley, MD, from Ann& Robert H. Lurie Children's Hospital of Chicago, found that a regimen of three drugs (elexacaftor/tezacaftor/ivacaftor) that targets the genetic cause of cystic fibrosis was safe and effective in 6-11-year-olds with at least one copy of F508del mutation in the CFTR gene, which is estimated to represent almost 90 percent of the cystic fibrosis population in the United States. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 18, 2021 Category: International Medicine & Public Health Source Type: news

Singapore scientists develop novel gene editor to correct disease-causing mutations
(Agency for Science, Technology and Research (A*STAR), Singapore) The Genome Institute of Singapore (GIS) has developed a CRISPR-based gene editor to correct mutations that cause genetic disorders. The C-to-G Base Editor (CGBE) by GIS advances the widely adopted CRISPR-Cas9 technology to enable molecular surgery on the human genome. This invention opens up treatment options for approximately 40 per cent of single-base substitutions associated with human diseases - including cystic fibrosis, cardiovascular diseases, musculoskeletal diseases, and neurological disorders. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 11, 2021 Category: Biology Source Type: news

Research reveals how bacteria defeat drugs that fight cystic fibrosis
(The University of Montana) University of Montana researchers and their partners have discovered a slimy strategy used by bacteria to defeat antibiotics and other drugs used to combat infections afflicting people with cystic fibrosis. The research was published Feb. 23, 2021 in the journal Cell Reports. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 26, 2021 Category: Infectious Diseases Source Type: news

How do patients with cystic fibrosis respond to COVID-19?
(Boston Children's Hospital) Based on clinical data, patients with cystic fibrosis (CF) don't appear to be especially susceptible to COVID-19, and when they do get infected, they don't seem to get sicker. But Ruobing (Ruby) Wang, MD, a physician-scientist in the Division of Pulmonary Medicine at Boston Children's Hospital, cares for patients with CF and thinks there is more to the story. Thanks to a grant from the Cystic Fibrosis Foundation, Dr. Wang will put her theories to the test. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 22, 2021 Category: International Medicine & Public Health Source Type: news

NIH Director Francis Collins Is Fighting This Coronavirus While Preparing for the Next One
In May 2020, Dr. Francis Collins, the longtime head of the National Institutes of Health (NIH), was called to the White House to meet with Jared Kushner, the then President’s son-in-law and adviser, and Dr. Deborah Birx, the head of the White House Coronavirus Task Force. A few weeks earlier, Congress had given the NIH $1.5 billion to try to speed up the process of developing new diagnostic tests for COVID-19, and the White House, which was dubious about increasing the rate of testing, wanted to know more about what the NIH was doing. Collins is technically the boss of Dr. Anthony Fauci, but during the pandemic he ha...
Source: TIME: Health - February 4, 2021 Category: Consumer Health News Authors: Belinda Luscombe Tags: Uncategorized COVID-19 feature Magazine Source Type: news

Jamie Cary wins major CF award for her work as Certified Child Life Specialist at Upstate ’s Robert C. Schwartz Cystic Fibrosis Center
Cary was one of only two individuals nationwide to receive the Mary M. Kontos Care Champion Award from the Cystic Fibrosis Foundation at the North American Cystic Fibrosis Conference (NACFC) in October 2020. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - February 3, 2021 Category: Universities & Medical Training Tags: News Source Type: news

amie Cary wins major CF award for her work as Certified Child Life Specialist at Upstate ’s Robert C. Schwartz Cystic Fibrosis Center
Cary was one of only two individuals nationwide to receive the Mary M. Kontos Care Champion Award from the Cystic Fibrosis Foundation at the North American Cystic Fibrosis Conference (NACFC) in October 2020. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - February 2, 2021 Category: Universities & Medical Training Tags: News Source Type: news

Updated advice on COVID-19 vaccination in pregnancy and women who are breastfeeding, RCOG
The Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise Oxford University/AstraZeneca's COVID-19 vaccine for use. The Joint Committee on Vaccination and Immunisation (JCVI) has also published its latest advice for the priority groups to receive the Oxford University/AstraZeneca and the Pfizer/BioNTech vaccines. This includes updated advice for pregnant and breastfeeding women who meet other criteria for priority vaccination. The JCVI confirms that although the available data do not indicate any safety concern or harm to pregnancy, there is insuf...
Source: Current Awareness Service for Health (CASH) - December 31, 2020 Category: Consumer Health News Source Type: news

Antifungal drug improves key cystic fibrosis biomarkers in clinical study
(University of Illinois at Urbana-Champaign, News Bureau) A drug widely used to treat fungal infections improved key biomarkers in lung tissue cultures as well as in the noses of patients with cystic fibrosis, a clinical study by researchers at the University of Illinois Urbana-Champaign and the University of Iowa found. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 17, 2020 Category: Biology Source Type: news

Featured Review: Drugs for correcting the basic defect in the most common cystic fibrosis-causing gene variant
Read thisrecently published Cochrane review about CFTR correctors, a therapy for cystic fibrosis targeted at specific variants (most commonly F508del)In this review, the authors looked at drugs (or drug combinations) for correcting the basic defect in the most common cystic fibrosis (CF)-causing gene variant (F508del) and assessed their impact on outcomes important to people with Cystic Fibrosis, e.g. survival, quality of life (QoL), lung function and safety.Professor Kevin Southern, lead author of this review, has been involved in the care of children with CF for over 30 years, and has a deep appreciation of the impact of...
Source: Cochrane News and Events - December 16, 2020 Category: Information Technology Authors: Katie Abbotts Source Type: news

How Is a Person's Life Affected By Cystic Fibrosis?
Title: How Is a Person's Life Affected By Cystic Fibrosis?Category: Diseases and ConditionsCreated: 10/9/2020 12:00:00 AMLast Editorial Review: 12/10/2020 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - December 10, 2020 Category: Respiratory Medicine Source Type: news

Johns Hopkins develops potential antibiotic for drug-resistant pathogen
(Johns Hopkins University) Scientists from Johns Hopkins University and Medicine have developed a possible new antibiotic for a pathogen that is notoriously resistant to medications and frequently lethal for people with cystic fibrosis and other lung ailments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 8, 2020 Category: International Medicine & Public Health Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this ap...
Source: Roche Media News - December 1, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this ap...
Source: Roche Investor Update - December 1, 2020 Category: Pharmaceuticals Source Type: news

Telehealth Finds Acceptance Among Patients With Cf, Clinicians Telehealth Finds Acceptance Among Patients With Cf, Clinicians
Telehealth is widely accepted among individuals with cystic fibrosis (CF) and the physicians who treat them, according to three new studies.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 23, 2020 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

COVID-19 rapid guideline: cystic fibrosis, NICE (updated 7th October 2020)
The purpose of this guideline is to maximise the safety of patients with cystic fibrosis and make the best use of NHS resources, while protecting staff from infection.The guideline focuses on what you need to stop or start doing during the pandemic. Follow the usual professional guidelines, standards and laws (including those on equalities, safeguarding, communication and mental capacity), as described in 2 External 0 0 0 making decisions using NICE guidelines false https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-guidelines/making-decisions-using-nice-guidelines true false%>. On 7 October 2020...
Source: Current Awareness Service for Health (CASH) - November 20, 2020 Category: Consumer Health News Source Type: news

Why Is Meconium Ileus Diagnostic for Cystic Fibrosis?
Title: Why Is Meconium Ileus Diagnostic for Cystic Fibrosis?Category: Procedures and TestsCreated: 11/20/2020 12:00:00 AMLast Editorial Review: 11/20/2020 12:00:00 AM (Source: MedicineNet Kids Health General)
Source: MedicineNet Kids Health General - November 20, 2020 Category: Pediatrics Source Type: news

Understanding lung infections in patients with cystic fibrosis
(University of Warwick) For young people with cystic fibrosis, lung infection with Staphylococcus aureus, MRSA, is common and is treated with antibiotics in the hope that this will prevent a decline in lung function. However there has recently been debate over the role S. aureus plays in CF lung disease. Researchers from the University of Warwick have used a new model of CF lungs which could be used to make better decisions about future use of antibiotics. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 19, 2020 Category: Infectious Diseases Source Type: news

Former Gilead CEO lands on board of East Bay gene therapy company seeking $75M IPO
4D Molecular Therapeutics' gene therapies are mainly focused on the eyes, but includes potential one-and-done treatments for Fabry disease and cystic fibrosis. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 18, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Former Gilead CEO lands on board of East Bay gene therapy company seeking $75M IPO
4D Molecular Therapeutics' gene therapies are mainly focused on the eyes, but includes potential one-and-done treatments for Fabry disease and cystic fibrosis. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 18, 2020 Category: American Health Authors: Ron Leuty Source Type: news

Cystic Fibrosis Patients' Vulnerability to COVID-19 Infection Cystic Fibrosis Patients' Vulnerability to COVID-19 Infection
Clinicians treating patients with cystic fibrosis have had to face the possibility that their patients may be at greater risk of worse outcomes from COVID-19.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - November 11, 2020 Category: Emergency Medicine Tags: Pulmonary Medicine News Source Type: news

Respiratory platform NuvoAir shows high acceptance of its home spirometry
The platform has shared three studies presented at the 2020 North American Cystic Fibrosis (CF) conference. (Source: mobihealthnews)
Source: mobihealthnews - November 9, 2020 Category: Information Technology Source Type: news

Triple Combination Benefits CF Patients With Advanced Disease Triple Combination Benefits CF Patients With Advanced Disease
Triple combination therapy in cystic fibrosis patients with advanced lung disease appears to improve lung function, and may delay the need for lung transplant.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - November 6, 2020 Category: Infectious Diseases Tags: Pulmonary Medicine News Source Type: news

Genetic mutation could worsen heart function in Duchenne muscular dystrophy patients
(UT Southwestern Medical Center) DALLAS - Nov. 4, 2020 - A mutation in the gene that causes cystic fibrosis may accelerate heart function decline in those with Duchenne muscular dystrophy (DMD), a new study by UT Southwestern researchers suggests. The findings, published online recently in theJournal of the American Heart Association, could help doctors develop new strategies to preserve heart function in this population, potentially extending patients' lives. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 4, 2020 Category: International Medicine & Public Health Source Type: news

FDA Approves Bronchitol (mannitol) Inhalation Powder to Improve Pulmonary Function in Adult Patients with Cystic Fibrosis
CARY, N.C., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), received U.S. Food and Drug Administration (FDA) approval of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 2, 2020 Category: Drugs & Pharmacology Source Type: news

Let's (not) stick together
(University of Pittsburgh) New research led by the University of Pittsburgh's Swanson School of Engineering examines the properties of the mucus of cystic fibrosis (CF) patients and the role it plays in a pathogens' ability to survive. The new information could have important implications for CF treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 28, 2020 Category: International Medicine & Public Health Source Type: news

Armata Pharmaceuticals Appoints Mina Pastagia, MD, MS as Vice President of Clinical Development
Appointment adds extensive expertise in the development of anti-infectives, including bacteriophage therapy to treat P. aeruginosa infections in cystic fibrosis patients MARINA DEL REY, Calif., Oct. 26, 2020 -- (Healthcare Sales & Marketing Network) --... Biopharmaceuticals, Personnel Armata Pharmaceuticals, bacteriophage therapeutics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 26, 2020 Category: Pharmaceuticals Source Type: news

Twin left fighting for his life with cystic fibrosis has finally got £28,000 drug that will save him
Anthony Usher, from Liverpool, has cystic fibrosis, an incurable genetic condition that destroys the lungs and digestive system. (Source: the Mail online | Health)
Source: the Mail online | Health - October 24, 2020 Category: Consumer Health News Source Type: news

Researchers create human airway stem cells from patients' cells
(Boston Medical Center) For the first time, researchers have successfully created airway basal stem cells in vitro from induced pluripotent stem cells by reprogramming blood cells taken from patients. Given that airway basal cells are defined as stem cells of the airways because they can regenerate the airway epithelium in response to injury, this study may help accelerate research on diseases impacting the airway, including COVID-19, influenza, asthma and cystic fibrosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 23, 2020 Category: International Medicine & Public Health Source Type: news

Thirona obtains AI software patent for treatment of cystic fibrosis in children
The AI company will use the license to implement  a quantitative method for the analysis of chest CT scans. (Source: mobihealthnews)
Source: mobihealthnews - October 16, 2020 Category: Information Technology Source Type: news

Cystic fibrosis latest: New wonder drug Kaftrio gives hope to sufferers
Cystic fibrosis wonder drug Kaftrio is now being rolled out across the UK and today the Daily Express brings you the stories of renewed hope as sufferers reveal how it will transform their lives. (Source: Daily Express - Health)
Source: Daily Express - Health - October 11, 2020 Category: Consumer Health News Source Type: news

IV, Oral Antibiotics Comparable for Treating P. aeruginosa in CF
Results do not support use of IV antibiotics to eradicate P. aeruginosa in cystic fibrosis, authors say (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 8, 2020 Category: Respiratory Medicine Tags: Family Medicine, Infections, Internal Medicine, Pediatrics, Pharmacy, Pulmonology, Journal, Source Type: news

IV, Oral Antibiotics Comparable for Treating P. aeruginosa in CF
THURSDAY, Oct. 8, 2020 -- Intravenous antibiotics do not achieve greater sustained eradication of Pseudomonas aeruginosa in patients with cystic fibrosis compared with oral therapy, according to a study published in the October issue of The Lancet... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 8, 2020 Category: Pharmaceuticals Source Type: news

Treating cystic fibrosis with mRNA therapy or CRISPR
(Mary Ann Liebert, Inc./Genetic Engineering News) The potential for treating cystic fibrosis (CF) using mRNA therapies or CRISPR gene editing is possible regardless of the causative mutation. CF clinical trials showing that a genotype-agnostic gene therapy for CF is possible (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 8, 2020 Category: International Medicine & Public Health Source Type: news

COVID-19 rapid guideline: cystic fibrosis [NG170], NICE (updated 7th October 2020)
On 7 October 2020, we withdrew our recommendations on reducing or deprioritising cystic fibrosis registry data entry, limiting transplant services and deferring transition to adult services because these emergency measures are no longer needed. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 7, 2020 Category: Consumer Health News Source Type: news

DDT COA #000007: The Cystic Fibrosis Respiratory Symptom Diary – Chronic Respiratory Infection Symptom Score (CFRSD-CRISS)
Clinical Outcome Assessments (COA) Qualification Submissions Office of Antimicrobial Products (OAP) Division of Anti-Infective Products (DAIP) DDT COA Number DDT COA #000007 (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 7, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Thirona licenses patent for cystic fibrosis AI software
Dutch artificial intelligence (AI) software developer Thirona said it has exclusively...Read more on AuntMinnie.comRelated Reading: Thirona, Smart Reporting team up on COVID-19 software Free AI software can help triage COVID-19 on x-ray Thirona unveils AI software for COVID-19 analysis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 6, 2020 Category: Radiology Source Type: news